Project partners
The project consortium consists of 25 partners from 12 countries and more than 200 researchers are currently working on the project.
Successful development of protein kinase inhibitors requires a multidisciplinary approach. The consortium includes academic groups with unique expertise in biochemistry, structural crystallography, synthetic organic chemistry, lead structure optimisation and other fields of rational drug discovery.
| University of Helsinki Faculty of Pharmacy Division of Pharmacology and Toxicology and Viikki Drug Discovery Technology Center (DDTC) Prof. Raimo K. Tuominen (project coordinator) Prof. Jari Yli-Kauhaluoma and Faculty of Agriculture and Forestry, Department of Applied Chemistry and Microbiology Prof. Kaarina Sivonen Prof. Annele Hatakka Helsinki, Finland |
CNRS
Lyon Méthodologies de Synthèse et Molécules Bioactives, Université Claude Bernard Lyon 1 Prof. Peter Goekjian Prof. Hélène Parrot-Lopez Prof. Benoît Joseph Prof. Olivier Piva Dr. Philippe Belmont and Université Blaise Pascal - Clermont-Ferrand II Prof. Michelle Prudhomme France |
| The Hebrew University of Jerusalem - Hadassah Medical School Prof. Charles L. Jaffe Prof. Alexander Levitzki Jerusalem, Israel |
Ludwig Maximilians University Munich Department of Pharmacy Prof. Angelika Vollmar Dr. Stefan Zahler München, Germany |
| Université
de Genève Laboratoire de Pharmacognosie et de Phytochimie Section des Sciences Pharmaceutiques Prof. Andrew Marston Geneva, Switzerland |
Université de Genève Laboratoire de chimie thérapeutique Section de pharmacie Prof. Leonardo Scapozza Geneva, Switzerland |
| University of Dundee School of Life Sciences Prof. Sir Philip Cohen Scotland, UK |
University of Birmingham Department of Immunology Prof. Janet M. Lord Birmingham, UK |
| University of Debrecen Medical and Health Science Center Department of Biophysics and Cell Biology Prof. János Szöllõsi Prof. György Vereb Debrecen, Hungary |
University of Milano-Bicocca Professor of Internal Medicine Prof. Carlo Gambacorti-Passerini Monza, Italy |
| University of Innsbruck Institute of Pharmacy Prof. Thierry Langer Innsbruck, Austria |
KTB
Tumorforschungs GmbH ProQinase Dr. Michael Kubbutat Freiburg, Germany |
| CR-UK London Research Institute Prof. Peter J. Parker Dr. Neil Mcdonald London, UK |
CNRS Roscoff, Station Biologique Prof. Laurent Meijer Roscoff, France |
| C3Biotech Dr. Paul Pechan Otterfing, Germany |
Neurokin S.A.R.L. Dr. Serge Timsit Dr. Benedicte Menn Marseilles, France |
| Venetian Institute for Molecular Medicine (VIMM) and University of Padova, Departments of Biological Chemistry and Organic Chemistry Prof. Lorenzo A. Pinna Prof. Giuseppe Zanotti Padova, Italy |
University of Oxford Department of Biochemistry Prof. Dame Louise Johnson Dr. Aude Echalier Dr. Jane A. Endicott Dr. James McDonnell Dr. Martin E.M. Noble Oxford, UK |
| University of Bergen Apoptosis Signaling Group (APSIB) Prof. Stein-Ove Døskeland Bergen, Norway |
Institute of Neurobiology of the Mediterranean Sea (INMED / INSERM) Dr. Yehezkel Ben-Ari Dr. Anton Ivanov Marseille, France |
| Inte:Ligand Software Development Unit Dr. Gerhard Wolber Vienna, Austria |
Pepscan Systems BV Dr. Peter van Dijken Dr. Jos Joore Lelsyatd, The Netherlands |
| Technische Universität Braunschweig Institut für Pharmazeutische Chemie Prof. Conrad Kunick Braunschweig, Germany |
Innsbruck Medical University Institute of Medical Chemistry and Biochemistry Prof. Johann Hofmann Innsbruck, Austria |
| University of Vienna Department of Pharmacognosy Prof. Verena M. Dirsch, Ph.D Vienna, Austria |
Gause Institute of New
Antibiotics Prof. Maria N. Preobrazhenskaya Moscow, Russia |
Research
Center fro Biotechnology of Antibiotics Prof. Valery Danilenko Moscow, Russia |